Literature DB >> 8666858

Xanthomonas maltophilia and Pseudomonas cepacia in lower respiratory tracts of patients in critical care units.

E Maningo1, C Watanakunakorn.   

Abstract

Xanthomonas maltophilia and Pseudomonas cepacia are Gram-negative bacilli that are considered to opportunistic pathogens. These bacteria may cause colonization and infection, especially in acutely ill patients. Between 1 July 1990 and 30 June 1992 sputum [correction of suptum] culture results from patients in the critical care units were surveyed daily. During the 2 year period, sputum from 27 patients grew X. maltophilia. It was hospital-acquired in 26 patients. A total of 26 patients were mechanically ventilated for between 1 day and 8 months (median 19 days) before sputum cultures grew X. maltophilia. Various antimicrobial agents were prescribed for 25 of the 27 patients before they acquired X. maltophilia infection. The case fatality was 44.4%. Sputum from 79 patients grew P. cepacia. It was hospital-acquired in all who were ventilated for between 1 day and 50 days (median 9 days) before sputum cultures grew P. cepacia. Several antimicrobial agents were given to 77 patients before P. cepacia was isolated from them. The case fatality rate was 51.9%. In the majority of cases, the positive cultures indicated colonization. Patients with APACHE II scores >15 experienced a higher fatality (55.6% vs. 22.2%, P<0.05 for X. maltophilia and 56.9% vs.28.6%, P<0.05 for P. cepacia).

Entities:  

Mesh:

Year:  1995        PMID: 8666858     DOI: 10.1016/s0163-4453(95)91985-6

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  9 in total

1.  Multiple antibiotic resistance in Stenotrophomonas maltophilia: involvement of a multidrug efflux system.

Authors:  L Zhang; X Z Li; K Poole
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

2.  Multiple antibiotic resistance in Stenotrophomonas maltophilia.

Authors:  A Alonso; J L Martínez
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

3.  Antibacterial activity of BMS-180680, a new catechol-containing monobactam.

Authors:  J Fung-Tomc; K Bush; B Minassian; B Kolek; R Flamm; E Gradelski; D Bonner
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

4.  Stenotrophomonas maltophilia infection among young children in a cardiac intensive care unit: a single institution experience.

Authors:  Ciji Arthur; Xinyu Tang; Jose R Romero; Jeffrey G Gossett; Nada Harik; Parthak Prodhan
Journal:  Pediatr Cardiol       Date:  2014-10-08       Impact factor: 1.655

Review 5.  Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia.

Authors:  M Denton; K G Kerr
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

Review 6.  Antimicrobial therapy for Stenotrophomonas maltophilia infections.

Authors:  A C Nicodemo; J I Garcia Paez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-04       Impact factor: 3.267

7.  Antibiogram of Stenotrophomonas maltophilia Isolated From Nkonkobe Municipality, Eastern Cape Province, South Africa.

Authors:  Anthony Ayodeji Adegoke; Anthony I Okoh
Journal:  Jundishapur J Microbiol       Date:  2014-12-10       Impact factor: 0.747

8.  Stenotrophomonas maltophilia Infections in Adults: Primary Bacteremia and Pneumonia.

Authors:  Mustafa Gokhan Gozel; Cem Celik; Nazif Elaldi
Journal:  Jundishapur J Microbiol       Date:  2015-08-22       Impact factor: 0.747

9.  Outcomes of Stenotrophomonas maltophilia hospital-acquired pneumonia in intensive care unit: a nationwide retrospective study.

Authors:  Philippe Guerci; Hugo Bellut; Mokhtar Mokhtari; Julie Gaudefroy; Nicolas Mongardon; Claire Charpentier; Guillaume Louis; Parvine Tashk; Clément Dubost; Stanislas Ledochowski; Antoine Kimmoun; Thomas Godet; Julien Pottecher; Jean-Marc Lalot; Emmanuel Novy; David Hajage; Adrien Bouglé
Journal:  Crit Care       Date:  2019-11-21       Impact factor: 9.097

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.